Mutant Epidermal Growth Factor Receptor (EGFR) oncoproteins lacking most of subdomains I and II of the extracellular region, a deletion which includes most of the ®rst of two cysteine-rich sequences, have been observed in multiple human epithelial tumors, including malignant gliomas. These EGFR oncoproteins, designated DEGFR or EGFRvIII, confer increased tumorigenicity in vivo and are often coexpressed with fulllength EGFR in human tumors. We have expressed an ectodomain-derived, carboxyl-terminal deletion mutant of the p185neu oncogene (T691stop) in human glioblastoma cells coexpressing endogenous EGFR and activated DEGFR oncoproteins. The p185neu ectodomain-derived mutant forms heterodimers with DEGFR proteins and reduces the phosphotyrosine content and kinase activity of DEGFR monomers. As a consequence of T691stop neu expression and surface localization, cell proliferation in conditions of full growth and reduced serum and anchorage-independent growth in soft agar was reduced in glioblastoma cells expressing either endogenous EGFR alone or coexpressing EGFR and elevated levels of DEGFRs. T691stop neu mutant receptors abrogate the dramatic growth advantage conferred by DEGFR in vivo, suggesting that physical associations primarily between subdomains III and IV of the p185neu and EGFR ectodomains are sucient to modulate signaling from activated EGFR complexes. Receptor-based inhibitory strategies exploit the thermodynamic preference for erbB ectodomains to heterodimerize, thereby creating erbB receptor assemblies which are defective in signaling and do not internalize. Pharmaceuticals which mimic the p185neu ectodomain may therefore have important therapeutic applications in advanced human malignancies expressing erbB receptors.
Introduction
Ligand-induced receptor dimerization is thought to account for the activation of eukaryotic signaling through transmembrane receptor tyrosine kinases (RTKs) (reviewed in Heldin, 1995) . Alterations of receptor subunits as a result of structural changes may be coupled to receptor oligomerization resulting in ampli®cation of signaling (Gadella and Jovin, 1995) . In addition to the binding of ligand, the erbB family of eukaryotic RTKs is regulated by interdomain interactions in cis (Bertics and Gill, 1985; Honegger et al., 1987 Honegger et al., , 1990 Weiner et al., 1989; Wells et al., 1990; Wiley et al., 1991; Helin and Beguinot, 1991; Sorkin et al., 1991; Guy et al., 1992; Myers et al., 1992; LeVea et al., 1993; Opresko et al., 1995) and trans (Wada et al., 1990; Samanta et al., 1994; Carraway and Cantley, 1994; Karunagaran et al., 1995 Karunagaran et al., , 1996 PinkasKramarski et al., 1996a,b) . Worthylake and .
Receptor activation of the erbB family involves both homodimer and heterodimer assembly formation (Ullrich and Wada et al., 1990; Carraway and Cantley, 1994; O'Rourke et al., 1997b) . In many cases, the formation of heterodimers between erbB family members increases ligand-binding anity and results in the formation of a more active signaling complex which in¯uences cell phenotype (Kokai et al., 1989; Wada et al., 1990; Alimandi et al., 1995; Pinkas-Kramarski et al., 1996a,b) . Using p185neu and EGF receptor mutants, we have previously shown that the ectodomain alone of these erbB receptors is sucient to allow for a thermodynamically preferred heteromeric physical association and that cytoplasmic contacts in the resultant dimer aect ligand anity, signaling and phenotype (Qian et al., 1994a, b; O'Rourke et al., 1997a, b) . Biochemical analysis of p185neu and EGFR suggests that the consequences of dimer formation between extracellular domains alone is dierent from the signaling resultant from endodomain dimer formation (Qian et al., 1994a . p185neu ectodomain-derived mutants are capable of speci®c trans-inhibition of EGF receptor signaling in both murine ®broblasts and primarily transformed EGFRoverexpressing human cells (Qian et al., 1994a; O'Rourke et al., 1997a) . The active receptor complex for Neu Dierentiation Factor (NDF/heregulin) appears to be either an erbB2-erbB3 or erbB2-erbB4 heterodimer, suggesting that p185neu/erbB2 functions, in part, as a trans-regulator of other erbB family receptor kinases Karunagaran et al., 1996; PinkasKramarski et al., 1996b) .
To further examine receptor subdomains responsible for trans regulatory interactions mediated by the extracellular domain in the erbB family, we analysed the interaction between the EGFR and p185neu/cerbB2 in transformed cells. An EGFR oncoprotein commonly observed in human glial neoplasms and other human epithelial malignancies (DEGFR or EGFRvIII) results from an in-frame truncation involving exons 2 through 7 (amino acids 6 to 273) in the gene encoding the extracellular region of the molecule resulting in the expression of truncated, constitutively phosphorylated DEGFRs of 140 ± 155 kDa (Nishikawa et al., 1994; Moscatello et al., 1995; Reist et al., 1995) . DEGF receptors have been observed to exist spontaneously in a dimeric form and mediate constitutive signaling and oncogenic transformation of rodent ®broblasts in a ligand-independent manner, while overexpressed p170 holo-EGFRs are only weakly transforming in the presence of EGF (Haley et al., 1989; Carter and Kung, 1994; Qian et al., 1994a; Moscatello et al., 1996) . Importantly, DEGFR oncoproteins confer a dramatic growth advantage in vivo in human glioblastoma cells (Nishikawa et al., 1994) and in murine ®broblasts (Moscatello et al., 1996) .
Recent reports indicate that DEGF receptors are present on the cell surface and internalize more slowly than ligand-stimulated holo-EGFRs (Moscatello et al., 1996; Huang et al., 1997) , which may increase transforming eciency of DEGFR oncoproteins (Chen et al., 1989; Wells et al., 1990; Masui et al., 1991; Huang et al., 1997) . Other mutations which functionally separate the extracellular domain from the transmembrane and cytoplasmic region of RTK polypeptides have also been observed to lead to spontaneous dimerization (Sorokin, 1995) and to the acquisition of transforming potential (Haley et al., 1989; Sorokin, 1995) , suggesting that a portion of the extracellular domain imposes a structural constraint on dimer formation which is presumably removed by ligand-binding or mass action. Extracellular deletions observed in DEGFRs or avian v-erbB oncogenes presumably facilitate dimer formation by mimicking the conformational changes resulting from ligandbinding. Soluble extracellular domains of the EGFR have been observed to oligomerize (Kohda et al., 1993) and structural alteration in the ectodomain can induce spontaneous oligomerization of extracellular domains, cytoplasmic domains, or both (Hurwitz et al., 1991; Mohammadi et al., 1993; LeVea et al., 1993; Samanta et al., 1994; Sorokin, 1995; Cochran and Kim, 1996) .
The extracellular deletion in DEGFR removes the majority of amino acids comprising subdomains I and II of the EGFR (see Kohda et al., 1993; Carter and Kung, 1994) , which includes a large portion of the ®rst (more amino-terminal) of two cysteine-rich sequences in the extracellular region of the receptor (Sugawa et al., 1990; Ekstrand et al., 1992; Wong et al., 1992) . Subdomain III, which has been reported to confer ligand-binding properties to the EGFR (Kohda et al., 1993) , is preserved in the DEGFR oncoprotein, although DEGFRs do not appear to bind ligand in NIH3T3 cells (Moscatello et al., 1996) . Coexpression of holo-EGFRs and DEGFRs has been observed in human glioblastoma and other tumor samples, suggesting that EGFR/DEGFR co-expressing cells may be a close correlate of human disease (Sugawa et al., 1990; Nishikawa et al., 1994; Moscatello et al., 1995) . We have expressed an ectodomain-derived, carboxyl-terminal deletion mutant of the p185neu oncogene (T691stop neu), lacking the entire kinase domain and carboxyl-terminal autophosphorylation sites, in human glioblastoma cells coexpressing fulllength EGFR and DEGFRs to examine whether the p185neu ectodomain could associate with truncated, ectodomain-deleted DEGFRs and modulate DEGFRmediated signaling.
Results
Expression of EGFR and p185neu mutant forms in human glioblastoma cells U87MG human glioblastoma cells express elevated levels (&10 5 receptors/cell) of endogenous, wild-type EGFR (Nishikawa et al., 1994; O'Rourke et al., 1997a) . Three clonal derivatives of parental U87MG human glioblastoma cells were utilized for these studies: U87/T691-1 cells contain T691stop neu in the U87MG background; U87MG.DEGFR cells express elevated levels (&10 6 receptors/cell) of human DEGFR proteins in parental U87MG cells (Nishikawa et al., 1994; Huang et al., 1997) Rourke et al., 1997a) .
Immunoprecipitation and immunoblotting of EGFRs in U87MG.DEGFR cells revealed the presence of endogenous EGFR (170 kDa) and transfected DEGFRs running as a doublet species of M r &140 kDa and D155 kDa (Nishikawa et al., 1994; Han et al., 1996; Huang et al., 1997) (Figure 1b) . This pattern was also demonstrated for U87MG.DEGFR/T691s double transfectants. We used scanning densitometry to con®rm a stoichiometric ratio of DEGFR : EGFR of 10 : 1 by immunoprecipitation of cell lysates using mAb 528 reactive with the extracellular domains of EGFR and DEGFR, followed by immunoblotting with a polyclonal antisera reactive with EGFR in both U87MG.DEGFR cells ( Figure  1b ) and U87MG.DEGFR/T691s cells (data not shown).
We demonstrated that T691stop neu ectodomain eciently forms heterodimers with full-length, wild- (Figure 2 , lanes 1 ± 2, 4 ± 5). Flow cytometric analysis indicated that receptor association occurring at the cell-surface mediates inhibition of EGFR, rather than endocytosis and degradation (data not shown). These data are in agreement with prior studies performed in rodent ®broblasts (Qian et al., 1994a) . The T691stop neu ectodomain inhibited the EGF-induced phosphorylation of wild-type endogenous EGFR in U87MG-derived cells (Figure 3 , lanes 1 ± 4). DEGFR is constitutively phosphorylated in U87MG.DEGFR cells, while p170 EGFR is phosphorylated in U87MG parental cells and in U87MG.DEGFR cells only upon the addition of EGF (Figure 3 , lanes 1 ± 2, 5 ± 6).
Blotting with an antiphosphotyrosine antibody revealed that the lower molecular weight species (p140) of DEGFR is underphosphorylated relative to the p155 species in U87MG.DEGFR cells (Figure 3 , lanes 5 ± 6). Figure 2 Association between endogenous EGFR and truncated neu receptors in vivo and inhibition of EGF-induced downmodulation of EGFR in glioma cells expressing T691stop neu receptors. U87MG parental cells (lanes 1 ± 3) and U87/T691-1 cells (U87MG cells which express T691stop neu, lanes 4 ± 6) were precipitated with anti-EGFR mAb 528 (Oncogene Science) (lanes 1 ± 2,4 ± 5) or anti-neu 7.16.4 (O'Rourke et al., 1997a) (lanes 3, 6) after cross-linking with DTSSP (3,3'-dithiobis(sulfosuccinimidylpropionate) (2 mM) (Pierce) with (lanes 2, 3, 5, 6) or without (lanes 1, 4) EGF treatment (100 ng/ml at 378C for 10 ± 15 min). Immunocomplexes were analysed by SDS/8% PAGE under reducing conditions. EGFR (closed arrow, M r =170 kDa) was detected by immunoblotting with Ab-4 (Oncogene Science), a polyclonal antibody against human EGFR. Co-precipitated EGFR proteins were detected in U87/ T691-1 cells immunoprecipitated with anti-neu mAb 7.16.4 (lane 6). EGF treatment resulted in more ecient downmodulation of EGFR in U87MG cells (lanes 1, 2) than in U87/T691-1 cells (lanes 4, 5) p185neu ectodomain inhibits mutant EGFR signaling DM O'Rourke et al in reduced serum and, notably, in full-growth media in both EGFR/DEGFR-coexpressing glioblastoma cells and in parental U87MG cells containing endogenous EGFR only (Figure 4a ). Of note, U87MG.DEGFR/ T691s subclones proliferated less than parental U87MG cells lacking DEGFRs in both full-growth media and, to a greater degree, in reduced serum conditions.
Modulation of
DEGFR did not increase transforming eciency in vitro in anchorage-independent growth assays over parental U87MG cells (Figure 4b ). U87MG cells are primary transformed human cells containing multiple somatic genetic alterations, including deletions of p16 (He et al., 1995; Nishikawa et al., 1995) and in the putative protein tyrosine phosphatase gene, PTEN (Li et al., 1997) . Soft agar growth of U87MG.DEGFR/ T691s cells was reduced 41.3% and 45% compared to parental U87MG and U87MG.DEGFR cells, respectively. Inhibition of anchorage-independent growth achieved by T691stop neu proteins was more signi®cant in U87MG parental cells lacking DEGFR (mean 75.2% inhibition relative to parental U87MG cells in three independent experiments) ( Figure 4b ).
The DEGF receptor confers a selective growth advantage in vivo in the U87MG cell background (Figure 4c ) (Nishikawa et al., 1994) , while many studies have shown that holo-EGFRs are nontransforming in vivo, except under de®ned conditions in which p185neu receptors are co-expressed (Qian et al., 1992) . Expression of the T691stop mutant neu ecotodomain in U87MG cells was previously shown to preferentially inhibit the U87MG oncogenic phenotype when compared to a form of truncated p185neu (N691stop) which diers from T691stop by containing the protooncogenic transmembrane region (O'Rourke et al., 1997a) . T691stop neu protein expression abrogated the selective in vivo growth advantage mediated by DEGFR in U87MG cells ( Figure 4c ). This result was con®rmed by an analysis of three additional U87MG.DEGFR/T691s subclones (data not shown). The U87MG.DEGFR/T691s subclone shown exhibited growth kinetics which are similar to parental U87MG cells, though appeared to be more inhibited than U87MG cells in vivo. Inhibition observed in vivo for all U87MG.DEGFR/T691s subclones was directly related to the stoichiometry of T691stop mutant neu expression (data not shown).
The T691stop neu mutant forms heterodimers with DEGFR in vivo
Because of the genetic complexity of U87MG.DEGFR transfectants and U87MG.DEGFR/T691s doubly transfected subclones, and the multiple homodimeric and heterodimeric complexes migrating at similar molecular weights in gradient SDS ± PAGE analysis, we elected to employ the thiocleavable, membraneimpermeable cross-linker DTSSP to examine individual components of putative surface-localized heteromeric complexes. The mAb 528 was utilized to immunoprecipitate all EGFRs (wild-type and DEGFRs) which might form heteromers with mutant neu proteins. We detected co-precipitated DEGFR monomers from antineu immunocomplexes by in vivo cross-linking experiments using DTSSP. Cross-linking of U87MG.DEGFR/T691s cells and separating immunocomplexes by SDS/6 ± 8% PAGE under reducing conditions revealed evidence of heterodimer formation between T691stop neu proteins and the p140DEGFR, p155DEGFR, and p170EGFR forms ( Figure 5a ). Most of the T691stop neu mutant receptors associated with the p140DEGFR form using these methods, although faint bands identifying heterodimerized p155DEGFR and p170EGFR proteins were repeatedly observed. Identi®cation of DEGFR proteins on the cell surface of U87MG.DEGFR and U87MG.DEGFR/T691s double transfectants by¯ow cytometry supports the observations made with the membrane-impermeable crosslinker ( Figure 5a ). T691stop neu mutant receptors form heterodimers with DEGF receptors on the cell surface. The cell-surface localization of DEGFR mutant . Equal cell numbers were plated and starved in serumfree media for 24 h after attachment to 10 cm dishes. Cells were treated + EGF (lanes 2, 4, 6) (100 ng/ml at 378C for 10 ± 15 min), washed twice with cold PBS and solubilized with PI/RIPA buer (Qian, et al. 1996) . Lysates of equal protein concentrations as determined by the Bio-Rad assay (Bio-Rad Laboratories) were immunoprecipitated with anti-EGFR mAb 528 and immunocomplexes were analysed by SDS/8% PAGE under reducing conditions. Phosphorylated EGFRs were detected in parental U87MG (lane 2) and U87MG.DEGFR cells (lanes 5, 6), but not U87/T691-1 cells (lanes 3, 4). The phosphorylation of endogenous, full-length EGFR (170 kDa) was EGF-dependent in U87MG cells (lanes 1, 2) and in U87MG.DEGFR cells (lanes 5, 6). However, the phosphorylation of DEGFRs was not dependent on EGF treatment in U87MG.DEGFR cells (lanes 5, 6). (b) The above blot was stripped and reprobed with the polyclonal anti-EGFR antibody, Ab-4. The presence of all EGFRs (closed arrows) was con®rmed in the cell types treated as above. DEGFR proteins appear as a doublet of &140 ± 155 kDa, with the higher molecular weight species more signi®cantly phosphorylated (panel A, lanes 5, 6). All protein signals were visualized by the enhanced chemiluminescence (ECL) system (Amersham) p185neu ectodomain inhibits mutant EGFR signaling DM O'Rourke et al receptors has been con®rmed by several independent investigators using dierent methods (Nishikawa et al., 1994; Moscatello et al., 1996; Wikstrand et al., 1997) . Blotting with an antiphosphotyrosine antibody con®rmed that both DEGFR species associated with T691stop neu are underphosphorylated (Figure 5b , lane 6). We consistently demonstrated negligible phosphotyrosine content for DEGFR monomers immunocomplexed to T691stop neu receptors in all experiments. EGF has been observed to increase the eciency of heterodimer formation between p170EGFR and the neu ectodomain, although this association is ligandindependent (O'Rourke and Greene, unpublished data). EGF minimally increased the formation of DEGFR-p185neu ectodomain immunocomplexes, suggesting that EGF may stabilize heteromeric formation, if not DEGFR homodimeric formation (Nishikawa et al., 1994; Qian et al., 1994a; Moscatello et al., 1996) .
Reduction of phosphotyrosine content of DEGFR monomers in vivo by T691stop neu coexpression
The phosphotyrosine content for DEGFR monomers immunocomplexed to T691stop neu receptors was negligible in all experiments (Figure 5a , b; lane 6). Our results also revealed that the lower molecular weight form of DEGFR (140 kDa) was relatively underphosphorylated as compared to the p155DEGFR form in both U87MG.DEGFR cells and U87MG.DEGFR/T691s double transfectants ( Figures  3 and 5b) , as reported previously .
Dierences in the phosphotyrosine content of DEGFR monomers between U87MG.DEGFR cells and U87MG.DEGFR/T691s cells were not observed in immunoprecipitations of larger cell lysates using mAb 528, which reacts with all EGFR forms ( Figure  1b) , for in vivo cross-linking experiments (Figure 5a , b; lanes 3, 5). Therefore, in order to speci®cally examine the phosphotyrosine content in vivo of DEGFRs in T691stop neu-expressing cells, an antibody reactive with the DEGFR only was used to precipitate DEGFRs from cell lysates containing reduced protein concentrations from those required to detect heterodimeric complexes. Blotting with PY-20 after immunoprecipitating with mAb D124 reactive with DEGFR only revealed several phosphoproteins in U87MG.DEGFR and U87MG.DEGFR/T691s cells ( Figure 5c, lanes 1,  2) . The slower migrating form of DEGFR (155 kDa) is indicated by the arrow, while the identities of the two other DEGFR-associated phosphoproteins are unknown. Using these smaller protein lysates, the faster migrating form of DEGFR (140 kDa) was not detected by the PY-20 antibody, indicating relatively lower 4 cells of each cell line were plated in 6 ± well plates and allowed to attach in full-growth media. The next day, the cells were either maintained in full-growth media (10%-FBS) or changed to 2%-FBS serum. Cells were allowed to grow for 4 days and were then trypsinized and counted. Parental U87MG cells were used for normalization (growth ratio=1.0 for all experiments). The growth of all derived cell lines was expressed as a fraction of the parental cell line for comparison. U87MG.DEGFR cells express endogenous EGFR and DEGFRs, U87MG.DEGFR/T691s cells express EGFR, DEGFR, and T691stop neu, and U87/T691-1 cells express endogenous EGFR and T691stop neu proteins. Each data point is a mean of triplicate samples. These data were con®rmed by three independent analyses under both full-growth and reduced serum conditions for each glioma cell line. (b) Anchorage-independent growth. 1000 ± 3000 cells of each cell line were seeded in soft agar dishes and cultured for 21 ± 28 day as described (O'Rourke et al., 1997a) . Colonies were then visualized and counted after staining. Each experiment was performed in triplicate. The mean and standard deviation of colonies 40.3 mm is shown. Each point is a mean of triplicate samples. This is a representative experiment which was con®rmed on three occasions. (c) Comparison of tumor growth in athymic mice between U87MG-derived cells lines. 10 6 cells of each cell line were injected intradermally on day 0 and tumor volume was recorded 1 ± 2 6/week. U87MG cells were injected on one side and the transfected cell line was injected into the contralateral side of the animal. Data represents the mean and standard deviation (s.d.) of tumors derived from each cell line (U87MG.DEGFR, n=11; U87MG, n=19; U87MG.DEGFR/T691s, n=10). U87/T691-1 cells (n=9) did not form tumors by the end point of this experiment, which we previously observed (O'Rourke et al., 1997a) 3) were immunoprecipitated with mAb D124 reactive with DEGFR only (Huang et al., 1997) and blotted with either anti-phosphotyrosine mAb PY-20 (lanes 1, 2) or the anti-EGFR polyclonal antibody Ab-4 (lanes 3, 4). Equal cell numbers were plated with cells under the same conditions as in (a) in fullgrowth medium and cells were solubilized with PI/RIPA buer. Immunocomplexes were separated by SDS/8% PAGE under reducing conditions before immunoblotting. The higher molecular weight form of DEGFR (&155 kDa; single arrow, lanes 1, 2) has higher phosphotyrosine content than the lower form (&140 kDa, negligible phosphotyrosine content in this experiment using these smaller lysate concentrations (Figure 5b , lane 6), these data indicate that T691stop neu surface expression alone is sucient to reduce DEGFR monomeric phosphotyrosine content in trans. In T691stop neu-containing cells, the observed 33.7% reduction in phosphotyrosine content of immunoprecipitated DEGFR monomers may diminish signaling from the activated DEGF receptor complex, since the signaling complex may be a higher order multimer (O'Rourke et al., 1997a) and DEGFR has been reported to have a lower stoichiometry of phosphotyrosine content than EGF-stimulated wildtype EGFR (Huang et al., 1997) . Substrate binding and/or catalytic activity of the DEGFR receptor kinase could be altered by a reduction of monomeric DEGFR phosphotyrosine content. The lower level of constitutive phosphotyrosine content of DEGFR relative to ligand-stimulated wild-type EGFR may account for the disabling eect on in vivo growth behaviour of individual point mutations in terminal autophosphorylation sites of DEGFR (Huang et al., 1997) . Heterooligomers formed by the association between DEGFR dimers and T691stop neu dimers may be one mechanism for the reduction of DEGFR phosphotyrosine content and the phenotypic inhibition resulting from T691stop neu expression and surface localization.
Reduction of in vitro kinase activity of DEGFR by T691stop neu expression
Since we observed a reduction of monomeric DEGFR phosphotyrosine content in cells expressing T691stop neu mutant receptors (Figure 5c ), we investigated whether the catalytic activity of the DEGFR receptor kinase could be altered by T691stop neu protein expression. Using conditions identical to those which con®rmed the presence of DEGFRs in cross-linked T691stop neu-associated heterodimers (Figure 5a ), we showed that anti-DEGFR immune complexes had increased in vitro kinase activity in U87MG.DEGFR cells pretreated with a membrane-impermeable crosslinker (DTSSP) (Figure 5d; lanes 1, 2) , but not in doubly transfected cells expressing T691stop neu mutant receptors (Figure 5d; lanes 3, 4) . T691stop neu expression resulted in a striking inhibition of the trans-phosphorylation of the slower migrating form (155 kDa) of DEGFR, due to heterodimer formation con®rmed by using DTSSP (Figure 5a ; lane 6). These results were con®rmed on three independent occasions. Since the 155 kDa DEGFR is in higher abundance in both U87MG.DEGFR and U87MG.DEGFR/T691s cells (Figure 1b) , the T691stop neu-mediated reduction of catalytic activity of the DEGF receptor kinase may explain the phenotypic inhibition observed in doubly transfected human glioblastoma cells (Figure 4) . No signi®cant dierences were observed in the phosphorylation of the p140DEGFR form in these in vitro experiments; however, since this species was phosphorylated in vitro, a fraction may be phosphorylated in vivo. Inhibition of DEGF receptor catalytic activity was consistently observed for receptor trans-phosphorylation. At the lower protein concentrations used in in vitro kinase experiments (Figure 5d) , there was minimal phosphorylation of the exogenous Histone III substrate in all anti-DEGFR immune complexes (data not shown).
The phenotypic inhibition of DEGFR signaling mediated by T691stop neu mutant receptors in human gliomblastoma cells thus appears to result from: (1) heterodimer formation between T691stop neu proteins and both forms of DEGFR, although we observed increased heterodimer formation with p140DEGFR; (2) trans-inhibition of 155DEGFR monomeric phosphotyrosine content in vivo by T691stop neu expression; and (3) inhibition of trans-phosphorylation of the p155DEGFR kinase as a consequence of T691stop neu expression and heterodimer formation.
Discussion
U87MG cells in which constitutively active DEGF receptors are coexpressed with endogenous EGFR represent a close approximation of a particularly aggressive subset of human glioblastomas, those tumors in which p16 deletion, allelic loss on chromosome 10q, and EGFR activation occur, while p53 is nonmutated (Louis, 1997) . U87MG-derived human glioblastoma cells expressing endogenous EGFR, elevated amounts of DEGFR oncoproteins, and T691stop kinase-de®cient neu mutant receptors (U87MG.DEGFR/T691s doubly transfected subclones) were inhibited in all in vitro and in vivo assays more than parental U87MG cells. This represented a signi®cant reduction in the phenotype observed with expression of DEGFR oncoproteins alone in the U87MG background (U87MG.DEGFR cells), particularly in vivo. Given that wild-type EGFR overexpression alone is non-oncogenic in vivo, the observed formation of DEGFR-neu ectodomain heterodimers, and the ratio of DEGFR : EGFR proteins in these cells, it appears that the observed growth inhibition conferred by T691stop neu and exhibited by U87MG.DEGFR/T691s cells was mediated by disabling signaling through DEGF receptors rather than endogenous p170 EGFRs.
It is possible that T691stop neu mutant receptors disable a EGFR-DEGFR heterodimeric complex, although the stoichiometric ratio of DEGFR : EGFR is approximately 10 : 1 in U87MG.DEGFR cells and in U87MG.DEGFR/T691s cells. Unlike endogenous wildtype EGFR, DEGF receptor dimer formation (Moscatello et al., 1996) and autophosphorylation in glioma cells occur independently of ligand (Figure 3 ) (Nishikawa et al., 1994) and DEGFR-expressing NIH3T3 cells exhibit ligand-independent growth and transforming properties (Moscatello et al., 1996) , suggesting that oncogenic signaling results from p185neu ectodomain inhibits mutant EGFR signaling DM O'Rourke et al constitutively phosphorylated DEGFR dimers. Others have not identi®ed EGFR-DEGFR heterodimers in U87MG.DEGFR cells (W.K. Cavenee, personal communication). Additionally, tyrosine phosphorylation of kinase-de®cient mutants of DEGFR expressed in U87MG cells cannot be restored by activating wildtype EGFR with ligand treatment, suggesting a lack of substantial trans-phosphorylation between EGFR and DEGFRs (Huang et al., 1997) . Given the thermodynamic preference of p185neu/erbB2 proteins to heterodimerize with EGFR and other erbB receptors, DEGFRs may form dimers with p185neu ectodomainderived proteins more readily than with holo-EGFRs (Murali et al., 1996; Grous-Porta et al., 1997) .
We have shown that T691stop inhibits the phosphorylation of p170EGFR in U87MG cells, and that EGFR and DEGFR monomers immunocomplexed to T691stop neu proteins have a negligible phosphotyrosine content. The demonstration of association between T691stop and the DEGFR does not necessarily indicate a preferential association over p170 EGFR because DEGFR and EGFR are not expressed at comparable levels in these cells. Flow cytometric analysis of all EGFRs in U87MG.DEGFR and U87MG.DEGFR/T691s-expressing subclones indicated that expression of the p185neu ectodomain did not alter the total EGFR, wild-type EGFR, or DEGFR cell-surface populations either in U87MG cells containing endogenous EGFR only or in U87MG.DEGFR transfectants containing EGFR and DEGFR. This is consistent with the observation that p185neu ectodomains disable EGFR signaling through the formation of defective heteromeric or oligomeric receptor assemblies located on the cell surface, rather than by inducing DEGF receptor internalization and downmodulation.
Autophosphorylation of tyrosine residues on EGF receptors activates binding sites for signaling molecules and may also regulate the catalytic activity of the EGF receptor (Bertics and Gill, 1985) . We showed that the constitutive phosphotyrosine content of DEGFR monomers in vivo and the kinase activity of DEGFR in vitro is reduced in trans as a consequence of T691stop neu expression. The phenotypic inhibition observed in vitro and in vivo in U87MG cells coexpressing DEGFRs and T691stop neu proteins (U87MG.DEGFR/T691s cells) relative to DEGFRs alone (U87MG.DEGFR cells) could be due in part to reduced binding sites on DEGFRs for signaling molecules as a result of forming heterodimers with T691stop neu. Additionally, kinase activity for transphosphorylation of the DEGF receptor or other substrate(s) may also be reduced by a conformational change induced by associating with the T691stop neu mutant receptor. Our data support the argument that a dimunition of kinase activity for receptor transphosphorylation contributes to a reduction in transformation. In vitro kinase activity for an exogenous Histone substrate was observed to be much lower than for receptor trans-phosphorylation and was not appreciably altered by T691stop neu expression. Others have shown that the in vitro kinase activity of DEGFR for exogenous substrate is only minimally altered by substitutions of the carboxyl terminal autophosphorylation sites; the reduction of phosphotyrosine content in vivo as a consequence of carboxyl terminal point mutations in DEGFR appeared to more reliably correlate with phenotypic inhibition (Huang et al., 1997) . The level of inhibition achieved in vivo by the T691stop neu mutant expressed in U87MG.DEGFR cells was similar to that exhibited by a point mutant of the ATP-binding site in DEGFR or by a DEGFR mutant with substitution of tyrosines 1068, 1148, and 1173 (Huang et al., 1997) .
Previous studies using trans-dominant p185neu mutants have indicated that the ectodomains of p185neu and EGFR are sucient for physical association, and that EGFR signaling can be modulated with these kinase-negative p185neu mutants (Qian et al., 1994a; O'Rourke et al., 1997a) . Receptor interactions in the cytoplasmic domain determine productive signaling for both p185neu and EGF receptors (Qian et al., 1996) . In the absence of crystallographic data on the extracellular regions of p185neu and EGFR, the structural features of ectodomain interactions between these receptors are unde®ned. DEGF receptors have been observed to exist in a dimerized form in the absence of ligand (Moscatello et al., 1996) . Soluble extracellular regions of the EGFR have been observed to oligomerize in response to EGF after cross-linking, although proteolytic fragments derived from subdomain III alone did not oligomerize (Kohda et al., 1993) , suggesting that other subdomains contribute to dimer formation. Subdomain III has been reported to confer ligand-binding properties to EGFR (Kohda et al., 1993) . Activated avian erbB oncogenes form homodimers in the absence of ligand with deletions of the entire extracellular region other than a portion of subdomain IV (second cysteine-rich domain) (Adelsman et al., 1996) . However, the physiologic significance of this observed homodimer formation was unclear since this did not correlate with tissue-speci®c transforming properties of these mutants (Adelsman et al., 1996) .
We have shown that physical association can occur between the p185neu and EGFR extracellular regions in transformed cells, despite a deletion which includes most of two independent subdomains (I, II) in the extracellular region of the EGF receptor. Independently, we have recently shown that extracellular mutants of p185neu deleted of either subdomain I or II still retain the ability to form heterodimers with fulllength EGFR, con®rming that these sequences are not critical for p185neu/EGFR heteromeric physical associations (O'Rourke and Greene, unpublished observations). The phenotypic inhibition of DEGFR oncoproteins by T691stop neu proteins supports the argument that a physical association primarily governed by subdomains III and IV is sucient to modulate signaling. We would therefore predict that associations between these subdomains would be physiologically important for allosteric receptor activation. Based on an analysis of the transforming eciency of ®broblasts expressing wild-type human EGFR and extracellular subdomain deletion mutants of p185neu, subdomain III in p185neu appears to be the least relevant extracellular subdomain for the formation of a transforming p185neu/EGFR heterodimeric signaling complex (O'Rourke, Kao and Greene, unpublished observations), suggesting that subdomain IV-mediated interactions may be most important for the initiation and/or stabilization of homodimeric and heterodimeric receptor complexes.
Each of the two extracellular cysteine-rich domains in subdomain II and IV of p185neu and EGFR may possess a unique fold known as the`EGF fold' or cysteine knot'. The motif is characterized by a repeat of six cysteine residues and by at least two intrachain disul®de bonds (McDonald and Hendrickson, 1993; Isaacs, 1995) . Although a similar motif has been observed in other proteins, its presence is highly conserved in cytokines and transmembrane receptors, including the structurally resolved tumor necrosis factor (TNF) receptor (McDonald and Hendrickson, 1993) . Several tyrosine kinase receptors have been shown to contain these cysteine-rich domains (MurrayRust et al., 1993; Ward et al., 1995) and it is presumed that they adopt similar conformations to that of the TNF receptor (McDonald and Hendrickson, 1993) . Tumor necrosis factor (TNF) receptors have been observed as dimers in crystal structures of the uncomplexed form (Banner et al., 1993) . In this form, the last extracellular cysteine-rich domain forms the major dimeric contacts (Naismith et al., 1995) . In these studies, the membrane proximal domain is disordered perhaps due to the lack of the transmembrane region that holds this domain in a stable state. Thus, it is hypothesized that in the whole receptor, the last cysteine-rich domain just amino-terminal to the transmembrane sequence might be stabilized by the transmembrane sequence and possibly involved in the formation of functional dimers. Based on these observations, we have analysed the ectodomains of p185neu and EGFR. A high degree of sequence homology between the second cysteine-rich domain (subdomain IV) or p185neu and EGFR and the cysteine knot fold in the TNF receptor has been identi®ed. A simple comparison of sequences in the transmembrane proximal domains of the TNF and p185neu receptors shows at least four of six cysteines are conserved.
Regulation by trans-receptor interactions has been observed for all erbB family members, many of which exhibit altered expression or regulation in human epithelial malignancies. The physiologic tendency of this receptor family to form heteromeric associations suggests that targeting human erbB oncoproteins with structures or pharmaceuticals which mimic certain subdomains in the p185neu ectodomain might be achievable in certain human malignancies. Alternatively, the p185neu ectodomain cDNA could be delivered to erbB receptor-positive tumor cells in a gene therapy approach to human neoplasia. DEGFR oncoproteins are dierentially expressed in many human epithelial neoplasms and may represent a tumor-speci®c target, however, these receptors are not regulated by ligand binding, are constitutively phosphorylated, and internalize poorly. These features may limit eorts to inhibit signaling from DEGF receptors in human tumors. The preferred thermodynamic tendency for erbB heterodimer formation in the absence of ligand suggests that targeting erbB oncoproteins with the p185neu ectodomain, novel pharmaceuticals, or peptide mimetics relevant to dimer formation would be more eective in achieving growth inhibition than inhibiting ligand-induced activation with monoclonal antibodies or ligand-binding antagonists.
Materials and methods

Vector construction
The deletion mutant T691stop neu was derived from the rat oncogenic neu cDNA, pSV2Tneu (Bargmann et al., 1986) , containing a single point mutation in the transmembrane region. Site-directed mutagenesis was used to introduce a stop codon at the Thr-691 position in the endodomain as described (O'Rourke et al., 1997a) . This cytoplasmicdeleted form of p185neu, lacking the kinase catalytic domain and the carboxyl terminal autophosphorylation sites, was then inserted into a mammalian expression vector. A fragment containing the hygromicin r gene from pHYG (Qian et al., 1996) was subcloned into APtag-1 (Flanagan and Leder, 1990) , an alkaline phosphatase (AP) expression vector under control of the Maloney Leukemia Virus promoter and LTR (MuLVLTR). The AP gene was then replaced by the mutant T691stop neu cDNA. Thus, T691stop was expressed in the pMuLVLTR/T691stop/Hyg r expression vector.
Maintenance of cells and development of stably transfected cell lines
The U87MG parental human glioblastoma cell line and the previously reported U87MG.DEGFR human glioblastoma subclone containing human DEGF receptors (Nishikawa et al., 1994) were obtained from Dr Webster Cavenee (Ludwig Cancer Institute, San Diego, California). For stable cell transfections, ten micrograms of the pMuLVLTR/T691stop/Hyg r construct was transfected into U87MG.DEGFR cells via the lipofectamine reagent (GIBCO-BRL, Gaithersberg, MD) under conditions determined by transfections using the pCMV-b (bacterial b-galactosidase) (Clontech) reporter construct. Optimal transfection eciency was determined by chemiluminescence as detected by a luminometer (Tropix). All cells were cultured in Dulbecco's modi®ed Eagle's medium (DMEM, Bio-Whittaker, Walkersville, MD) with 10% fetal bovine serum (Hyclone, Ogden, UT), 100 U penicillin, 50 mg/ml streptomycin, and 2 mM L-glutamine (GIBCO-BRL). Cultured cells were maintained at 378C in 95% air/5% CO 2 U87MG.DEGFR cells were supplemented with 0.4 mg/ml G418 (Geneticin, GIBCO-BRL) for maintenance of DEGFR transgene expression.
For the development of U87MG-derived double transfectants expressing DEGFR and T691stop neu proteins, the media was supplemented with both G418 sulfate and hygromicin B. After 2 ± 3 weeks in selection media containing 70 mg/ml hygromicin B (Boehringer Mannheim) and 0.4 mg/ml G418 sulfate (Geneticin, GIBCO-BRL), established U87MG.DEGFR clones expressing T691stop neu (designated U87MG.DEGFR/T691 cells) were isolated and screened by¯ow cytometric analysis using mAb 7.16.4 against the neu ecotodomain (O'Rourke et al., 1997a). The medium for stably transfected subclones was supplemented with 0.4 mg/ml G418 sulfate and 35 ± 70 mg/ml hygromicin B for maintenance of transgene expression. Stably transfected cell lines were periodically checked by¯ow cytometric analysis with mAb 7.16.4 to document stable levels of T691stop neu transgene expression.
Metabolic labeling of cells followed by immunoprecipitation
Full details have been described previously by our laboratory (O'Rourke et al., 1997a) . Brie¯y, subcon¯uent cells (1610 6 ) are seeded overnight onto 10 cm dishes in full growth medium (10% FBS ± DMEM). The following day, cells are starved in cysteine-free DMEM for 1 h then pulsed with [
35 S]cysteine (50 mCi/ml) (Amersham) for 15 h in 3% dialyzed FBS-cysteine-free DMEM. Lysates are harvested after two washes in PBS using a PI/RIPA buer p185neu ectodomain inhibits mutant EGFR signaling DM O'Rourke et al (Qian et al., 1994b) . Immunoprecipitations are carried out on ice for 60 min and complexes are separated by binding to protein A-sepharose prior to separation by 8% SDS ± PAGE, drying, and exposure to ®lm. Monoclonal antibody 7.16.4 against the p185neu ectodomain has been described (Qian et al., 1994a,b; O'Rourke et al., 1997a) . Monoclonal antibody 528 against the extracellular domains of both EGFR and DEGFR was obtained from Oncogene Science. 5 mg of antibody was utilized for immunoprecipitating proteins from lysates recovered from 10 cm dishes.
Cross-linking studies, immunoprecipitations and Western blotting
Equal cell numbers were plated and cultured overnight in 10 cm dishes. Cells were starved for 24 h in serum-free media and were treated with EGF (100 ng/ml at 378C for 10 ± 15 min) and then washed twice with cold phosphatebuered saline (PBS). For cross-linking, PBS containing 2 mM DTSSP (3,3'-dithiobis(sulfosuccinimidylpropionate) (Pierce) was then added and cells were incubated at 238C for 30 min, with occasional rocking of the plates. The cross-linking reaction was quenched with buer containing 10 mM Tris HCl, 0.9% NaCl, and 0.1 M glycine. Cells were then washed twice with cold PBS and solubilized with PI/RIPA buer (Qian et al., 1996) . Cell lysates were subjected to immunoprecipitation with either anti-neu mAb 7.16.4, anti-EGFR mAb 528, or anti-DEGFR mAb D124. The immunocomplexes of neu proteins or EGFR proteins were then solubilized and separated by SDS ± PAGE gels (6 ± 8%), and transferred onto nitrocellulose before immunoblotting with either the polyclonal anti-EGFR antibody, Ab-4 (Oncogene Science) or the antiphosphotyrosine mAb PY-20 (Santa Cruz Biotechnology, Santa Cruz, CA).
In vitro kinase assay
Cells were plated in 100 mm culture dishes and the next day were washed twice in ice cold PBS and lysed in 1 ml of lysis buer (50 mM HEPES, pH 7.5, 150 mM NaCl, 3% Brij-35, 2 mM EDTA, 0.02 mg/ml Aprotinin, 10% glycerol, 1.5 mM MgCl 2 ). Cell lysates were centrifugated at 20 000 g for 15 min. Protein concentrations of cell lysates were measured with the Dc Protein Assay (BioRad). Forty microliters of 50% (vol/vol) protein Asepharose were used to collect the immune complexes, which were then washed three times with wash buer (50 mM HEPES, 150 mM NaCl, 0.1% Brij-35, 2 mM EDTA, 0.01 mg/ml Aprotinin, 0.3 mM Na 3 VO 4 ). The pellets were suspended in 20 microliters of 20 mM HEPES (pH 7.4, 5 mM MnCl 2 , 0.1% Brij-35, 0.03 mM Na 3 Vo 4 , 0.02 mg/ml Aprotinin) containing 5 mCi of [ 32 P]g-ATP, and incubated at room temperature for 30 min. The reaction was terminated by the addition of 36 electrophoresis sample buer containing 2 mM ATP. After incubation at 1008C for 3 min, samples were then analysed by SDS ± PAGE.
In vitro and in vivo tumorigenicity assays Cell growth in full or reduced serum conditions was assessed as follows: 2610 4 cells of each cell line were plated in 6-well plates and allowed to attach in full-growth media. The next day, the cells were either maintained in full-growth media (10%-FBS) or changed to 2%-FBS serum. Cells were allowed to grow for 4 days and were then trypsinized and counted.
Anchorage-independent growth was determined by assessing the colony-forming eciency of cells suspended in soft agar. 1 ± 3610 3 cells were suspended in a 1 ml top layer (0.18% agarose/10% FBS ± DMEM) in 6 cm culture dishes containing a 3 ml cell-free feeder layer consisting of 0.25% agarose in DMEM supplemented with 10% FBS and 20 mM HEPES (pH 7.5). Colonies (40.3 mm) were visualized and counted on day 21 ± 28 for all cell lines after staining with piodonitrotetrazolium violet (1 mg/ml). Each cell line was examined in triplicate for three separate experiments.
Six to eight-week-old NCr homozygous nude mice were purchased from the National Cancer Institute. Cells (1610 6 ) were suspended in 0.1 ml of PBS and injected intradermally into the mid-dorsum of each animal. Parental U87MG cells were injected on one side of individual animals and stably transfected cell lines were injected on the contralateral side to make direct comparisons of growth within each animal. PBS alone was also injected into each animal as an additional control. Animals were maintained in accordance with the guidelines of the Committee on Animals of the University of Pennsylvania and those prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resource. Tumor growth is monitored twice weekly for 10 ± 12 weeks. Tumor size was calculated by measuring tumor volume (length6width6thickness).
Antibodies
Monoclonal antibody (mAb) 7.16.4 reactive with the ectodomain of p185neu has been described previously (Qian et al., 1994a; O'Rourke et al., 1997a) . The antiphosphotyrosine antibody, mAb PY-20, was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). mAb 528 (Ab-1) reactive with the extracellular region of EGFR and DEGFR was purchased from Oncogene Science (Uniondale, NY). mAb D124 reactive with the DEGFR only (Huang et al., 1997) was obtained from Dr Webster K Cavenee, Ludwig Cancer Institute, San Diego, CA. The polyclonal antibody Ab-4, reactive with the EGFR and utilized for immunoblotting, was obtained from Oncogene Science (Uniondale, NY).
